Oculis Holding AG (NASDAQ:OCS) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• Oculis has a “Moderate Buy” consensus rating from 10 analysts, with nine buys and one sell. The average 12-month price target is $38.00, well above the reported share price of $13.09.
• Several analysts recently cut their price targets, including Stifel Nicolaus to $40, Guggenheim to $45, and Robert W. Baird to $38, while maintaining bullish ratings.
• Oculis remains a clinical-stage biopharmaceutical company with significant losses: it reported a quarterly loss of $0.20 per share on $0.38 million in revenue, and institutional investors own 22.30% of the stock.

Shares of Oculis Holding AG (NASDAQ:OCS - Get Free Report) have received a consensus rating of "Moderate Buy" from the ten analysts that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and nine have assigned a buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $38.00.

Several research analysts have issued reports on the company. Wall Street Zen upgraded Oculis from a "strong sell" rating to a "sell" rating in a research report on Saturday, August 8th. Stifel Nicolaus cut their price target on shares of Oculis from $50.00 to $40.00 and set a "buy" rating for the company in a report on Monday, June 1st. Guggenheim reduced their price objective on shares of Oculis from $75.00 to $45.00 and set a "buy" rating for the company in a research note on Monday, June 1st. Robert W. Baird decreased their price target on Oculis from $49.00 to $38.00 and set an "outperform" rating on the stock in a research note on Monday, June 1st. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Oculis in a research report on Friday, July 17th.

Institutional Investors Weigh In On Oculis

A number of hedge funds and other institutional investors have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. increased its position in Oculis by 100.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 2,000 shares of the company's stock worth $40,000 after purchasing an additional 1,000 shares during the last quarter. Koshinski Asset Management Inc. purchased a new stake in shares of Oculis in the first quarter worth about $238,000. Millennium Management LLC acquired a new stake in shares of Oculis in the fourth quarter valued at about $312,000. Marshall Wace LLP acquired a new stake in shares of Oculis in the second quarter valued at about $393,000. Finally, Renaissance Technologies LLC acquired a new position in Oculis during the 4th quarter worth approximately $499,000. 22.30% of the stock is currently owned by hedge funds and other institutional investors.

Oculis Price Performance

Shares of NASDAQ OCS opened at $13.09 on Monday. The stock has a market cap of $758.96 million, a PE ratio of -7.52 and a beta of 0.51. The company has a quick ratio of 8.35, a current ratio of 8.35 and a debt-to-equity ratio of 0.01. Oculis has a 52-week low of $10.52 and a 52-week high of $34.47. The business has a 50-day moving average price of $12.42 and a 200 day moving average price of $21.27.

Oculis (NASDAQ:OCS - Get Free Report) last released its quarterly earnings results on Tuesday, June 30th. The company reported ($0.20) EPS for the quarter. Oculis had a negative return on equity of 42.61% and a negative net margin of 6,777.18%.The firm had revenue of $0.38 million for the quarter. Equities research analysts forecast that Oculis will post -2.01 earnings per share for the current year.

About Oculis

Oculis SA NASDAQ: OCS is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source